3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
9
Carcinoma, Hepatocellular
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
3
Colorectal Neoplasms
3
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Head and Neck Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Sarcopenia
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myositis
1
Metastatic Colorectal Adenocarcinoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Neoplasms
1
Hyperthermia
1
Histiocytoma, Malignant Fibrous
1
Hematologic Neoplasms
1
Heart Diseases
1
Glioma
1
Eye Diseases
1
Esophageal Squamous Cell Carcinoma
1
Interventions
Gemcitabine
7
Leucovorin
6
Irinotecan
6
Fluorouracil
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Capecitabine
4
Paclitaxel
3
Oxaliplatin
3
Ocoxin
3
Bevacizumab
3
pembrolizumab
2
entinostat
2
Sorafenib
2
Imatinib Mesylate
2
Everolimus
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
pralsetinib
1
palbociclib
1
irinotecan sucrosofate
1
halofantrine
1
guadecitabine
1
fludarabine
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Digestive System Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06022692
2023-09-05
HEAIS001
Zhejiang Hospital
Phase 1/2
Completed
18 enrolled